$HROW News

Harrow Announces Commercial Launch Of BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTISi And Developed By Samsung Bioepis

Is Harrow, Inc. (HROW) A Good Stock To Buy Now?

Can Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy?

Harrow Adds Another Piece To Ophthalmology Strategy

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Harrow Re-Launches Steroid-Sparing VERKAZIA For Vernal Keratoconjunctivitis, Targeting Underlying Inflammatory Mechanisms In Pediatric Patients

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism

Harrow Inc (NASDAQ:HROW): An Affordable Growth Play Combining Rapid Expansion with Reasonable Valuation

Harrow: Demand Keeps It Interesting, Valuation Keeps It A Hold

Harrow, Inc. 2026 Q1 - Results - Earnings Call Presentation

Mark Baum Buys Handful Of Shares In Harrow

Why Harrow (HROW) Narrative Is Shifting As Analysts Recut Targets Yet Stay Positive

The Harrow, Inc. (NASDAQ:HROW) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Cantor Fitzgerald Maintains Overweight on Harrow, Lowers Price Target to $88

Harrow Inc (HROW) Q1 2026 Earnings Call Highlights: Strong Product Demand Amid Revenue Challenges

Harrow Q1 Earnings Call Highlights

Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript

Harrow Health, Inc. Q1 2026 Earnings Call Summary

Transcript: Harrow Q1 2026 Earnings Conference Call